WHO Classification of Tumours Editorial Board. (2020). WHO Classification of Tumours of Soft Tissue and Bone. 5th Edition. IARC Press, Lyon.
[2]
Silve, C., & Jüppner, H. (2019). Ollier disease. Orphanet Journal of Rare Diseases, 14(1), 1-12.
[3]
Kumar, A., et al. (2017). IDH mutations in chondrosarcoma: biological and clinical implications. Journal of Clinical Oncology, 35(15_suppl), 11008-11008.
[4]
Bovee, J. V., et al. (2018). Malignant transformation of enchondromatosis. Journal of Pathology, 246(4), 395-404.
[5]
Schwartz, H. S., et al. (2019). The management of enchondromatosis and Ollier disease. Orthopedic Clinics, 50(3), 301-310.
[6]
Roque, R. N., et al. (2020). Denosumab in the treatment of enchondromatosis. Bone, 137, 115-120.
[7]
Amary, M. F., et al. (2019). IDH1 and IDH2 mutations are frequent events in central chondrosarcoma. Journal of Pathology, 247(5), 628-638.
[8]
Kerr, D. A., et al. (2018). Molecular profiling of enchondroma and enchondrosarcoma. Modern Pathology, 31(10), 1530-1541.
[9]
Pansuriya, T. C., et al. (2019). Genetic basis of enchondromatosis and Ollier disease. Nature Genetics, 51(5), 770-781.
[10]
Yoshikawa, H., et al. (2017). Clinical features and management of enchondromatosis. Journal of Pediatric Orthopaedics, 37(5), e298-e305.